İsmail Güler1, İhsan Kuzucu2, Deniz Baklacı3, Rauf Oğuzhan Kum4, Esra Özhamam Uçaryılmaz5, Müge Özcan4. 1. Deparment of Otorhinolaryngology, Ankara Medipol University School of Medicine, Ankara, Turkey. 2. Department of Otorhinolaryngology, Aksaray University School of Medicine, Aksaray, Turkey. 3. Clinic of Otorhinolaryngology, Kahramankazan State Hospital, Ankara, Turkey. 4. Clinic of Otorhinolaryngology, Ankara City Hospital, Ankara, Turkey. 5. Clinic of Pathology, Ankara City Hospital, Ankara, Turkey.
Abstract
OBJECTIVES: The aim of this study was to assess whether nivolumab is ototoxic in rats and whether this ototoxicity is dose-dependent. MATERIALS AND METHODS: Twelve rats were divided into two groups: Group 1 (control group, 6 rats, 12 ears) received intraperitoneal saline for 14 days. Group 2 (study group, 6 rats, 12 ears) and received two doses of 3 mg/kg intraperitoneal nivolumab within 14 days. Auditory brainstem responses (ABRs) were performed preoperatively and 4 and 8 weeks postoperatively. We compared between the groups, morphologic appearance of spiral ganglion cells and organ of Corti and density of spiral ganglion cells (measured with conventional light microscope connected to a personal computer). RESULTS: In our control group, both spiral ganglion and organ of corti had a normal morphological appearance. In our study group, spiral ganglion cells had a normal morphological appearance. However, some sections showed possibly mild degenerative changes in the organ of corti. Of 12 samples in the study group, four had a significant loss of density of spiral ganglion cells compared to the control group. The baseline ABR thresholds did not significantly differ between the groups (p=0.713). There was no statistically significant difference between the groups regarding ABR thresholds at week 4 (p=0.347). However, a statistically significant difference was observed in the ABR thresholds at week 8 (p=0.045). CONCLUSION: The results of our study showed that nivolumab treatment has ototoxic effects. Based on our results, we recommend monitoring the changes in the hearing ability of chemotherapy patients.
OBJECTIVES: The aim of this study was to assess whether nivolumab is ototoxic in rats and whether this ototoxicity is dose-dependent. MATERIALS AND METHODS: Twelve rats were divided into two groups: Group 1 (control group, 6 rats, 12 ears) received intraperitoneal saline for 14 days. Group 2 (study group, 6 rats, 12 ears) and received two doses of 3 mg/kg intraperitoneal nivolumab within 14 days. Auditory brainstem responses (ABRs) were performed preoperatively and 4 and 8 weeks postoperatively. We compared between the groups, morphologic appearance of spiral ganglion cells and organ of Corti and density of spiral ganglion cells (measured with conventional light microscope connected to a personal computer). RESULTS: In our control group, both spiral ganglion and organ of corti had a normal morphological appearance. In our study group, spiral ganglion cells had a normal morphological appearance. However, some sections showed possibly mild degenerative changes in the organ of corti. Of 12 samples in the study group, four had a significant loss of density of spiral ganglion cells compared to the control group. The baseline ABR thresholds did not significantly differ between the groups (p=0.713). There was no statistically significant difference between the groups regarding ABR thresholds at week 4 (p=0.347). However, a statistically significant difference was observed in the ABR thresholds at week 8 (p=0.045). CONCLUSION: The results of our study showed that nivolumab treatment has ototoxic effects. Based on our results, we recommend monitoring the changes in the hearing ability of chemotherapy patients.
Authors: Harrison W Lin; Daniel S Roberts; Jonathan Kay; Konstantina M Stankovic Journal: Otolaryngol Head Neck Surg Date: 2011-07-13 Impact factor: 3.497
Authors: Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert Journal: J Clin Oncol Date: 2016-11-14 Impact factor: 44.544
Authors: Lisa Zimmer; Simone M Goldinger; Lars Hofmann; Carmen Loquai; Selma Ugurel; Ioannis Thomas; Maria I Schmidgen; Ralf Gutzmer; Jochen S Utikal; Daniela Göppner; Jessica C Hassel; Friedegund Meier; Julia K Tietze; Andrea Forschner; Carsten Weishaupt; Martin Leverkus; Renate Wahl; Ursula Dietrich; Claus Garbe; Michael C Kirchberger; Thomas Eigentler; Carola Berking; Anja Gesierich; Angela M Krackhardt; Dirk Schadendorf; Gerold Schuler; Reinhard Dummer; Lucie M Heinzerling Journal: Eur J Cancer Date: 2016-04-13 Impact factor: 9.162
Authors: J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok Journal: Ann Oncol Date: 2015-09-14 Impact factor: 32.976
Authors: Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert Journal: JAMA Date: 2016-04-19 Impact factor: 56.272